{"id":"NCT02607930","sponsor":"Gilead Sciences","briefTitle":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","officialTitle":"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-13","primaryCompletion":"2017-05-09","completion":"2021-07-02","firstPosted":"2015-11-18","resultsPosted":"2018-07-23","lastUpdate":"2022-03-02"},"enrollment":631,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection"],"interventions":[{"type":"DRUG","name":"ABC/DTG/3TC","otherNames":["Triumeq®"]},{"type":"DRUG","name":"B/F/TAF","otherNames":["GS-9883/F/TAF","Biktarvy®"]},{"type":"DRUG","name":"ABC/DTG/3TC Placebo","otherNames":[]},{"type":"DRUG","name":"B/F/TAF Placebo","otherNames":[]}],"arms":[{"label":"B/F/TAF","type":"EXPERIMENTAL"},{"label":"ABC/DTG/3TC","type":"ACTIVE_COMPARATOR"},{"label":"Open-label Phase B/F/TAF to B/F/TAF","type":"EXPERIMENTAL"},{"label":"Open-label Phase ABC/DTG/3TC to B/F/TAF","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) in HIV-1 infected, antiretroviral treatment naive-adults.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm","timeFrame":"Week 48","effectByArm":[{"arm":"B/F/TAF","deltaMin":92.4,"sd":null},{"arm":"ABC/DTG/3TC","deltaMin":93,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.78"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":121,"countries":["United States","Belgium","Canada","Dominican Republic","France","Germany","Italy","Puerto Rico","Spain","United Kingdom"]},"refs":{"pmids":["29956087","31068270","30803969","28867497","32504574","33880558","39229805","38349226","37200995"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":314},"commonTop":["Upper respiratory tract infection","Syphilis","Nausea","Diarrhoea","Nasopharyngitis"]}}